Complement C5 inhibition in patients with COVID-19 - a promising target ?

Peffault de Latour, Regis; Bergeron, Anne; Lengline, Etienne; Dupont, Thibault; Marchal, Armance; Galicier, Lionel; de Castro, Nathalie; Bondeelle, Louise; Darmon, Michael; Dupin, Clairelyne; Dumas, Guillaume; Leguen, Pierre; Madelaine, Isabelle; Chevret, Sylvie; Molina, Jean-Michel; Azoulay, Elie; Fremeaux-Bacchi, Veronique; CORE group

doi:10.3324/haematol.2020.260117

Scientific article

Letter

English

Complement C5 inhibition in patients with COVID-19 - a promising target ?

Published inHaematologica, vol. 105, no. 12, p. 2847-2850

Publication date2020-12-01

First online date2020-12-01

Keywords

Antibodies, Monoclonal, Humanized / therapeutic use
COVID-19 / immunology
COVID-19 / virology
Complement C5 / antagonists & inhibitors
Complement Inactivating Agents / therapeutic use
Humans
Prognosis
SARS-CoV-2 / drug effects
SARS-CoV-2 / immunology
COVID-19 Drug Treatment

Affiliation entities

Not a UNIGE publication

Research groups

Maladies interstitielles et de l'immunodéprimé (1057)

Citation (ISO format)

PEFFAULT DE LATOUR, Regis et al. Complement C5 inhibition in patients with COVID-19 - a promising target ? In: Haematologica, 2020, vol. 105, n° 12, p. 2847–2850. doi: 10.3324/haematol.2020.260117

Article (Published version)

CC BY-NC-4.0

Identifiers

PID : unige:190542
DOI : 10.3324/haematol.2020.260117
PMID : 33256385
PMCID : PMC7716359

Additional URL for this publicationhttps://haematologica.org/article/view/9818

Journal ISSN0390-6078

12views

42downloads

Creation12/12/2025 12:56:14

First validation19/01/2026 13:15:57

Update19/01/2026 13:15:57

Status update19/01/2026 13:15:57

Last indexation19/01/2026 13:15:58

Archive ouverte UNIGE

Complement C5 inhibition in patients with COVID-19 - a promising target ?

Technical informations